May 18, 2017 10:01 AM EDT

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO

John Carroll

Editor & Founder

Roche has an early-stage T cell bispecific — which binds simultaneously to T cells and tumor cells — called CEA-TCB (RO6958688; RG7802) that it is bullish …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

#AS­CO17 high­lights: Roche ush­ers ear­ly-stage bis­pe­cif­ic in­to view; Agios, Cel­gene un­veil more AG-221 da­ta; Plen­ty more com­ing at AS­CO

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

#ASCO17 highlights: Roche ushers early-stage bispecific into view; Agios, Celgene unveil more AG-221 data; Plenty more coming at ASCO

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A